Predictions

Measuring R&D return on investment

4-year analysis of global pharmaceutical companies

Since 2010, Deloitte, in association with Thomson Reuters, has been quantifying the return on investment of selected life sciences companies.

Explore content

Measuring R&D return on investment

A decrease in R&D productivity has been a major business challenge in the pharmaceutical industry for years. Today, some companies are seeing improvement as a result of organizational transformation of R&D functions and external collaborations. Since 2010, Deloitte, in association with Thomson Reuters, has been quantifying the return on investment of selected life sciences companies. This paper will examine this improvement based on quantitative analysis of productivity and the return from compounds in late-stage development.

(397KB,PDF)
Did you find this useful?